Mitochon Pharmaceuticals develops mitochondrial-targeted oral therapies, principally MP101 and MP201, intended to provide broad neural protection across neurodegenerative and developmental disorders. The company reports striking preclinical benefits for MP101, including brain volume sparing in Huntington’s disease models, axonal protection in multiple sclerosis models, and motor improvements in Rett syndrome and Parkinson’s models. Mitochon completed its second year of funding with a total investment of $1.6 million to advance MP101 into human studies and to further develop MP201 toward an IND filing. The company plans Phase I studies in healthy volunteers in 2016 and anticipates studies in Huntington’s patients in 2017. Mitochon was founded in 2014 and is based in Blue Bell, Pa.

Total raised

$2M

Funding rounds

1

Latest round

Equity

Latest activity

May 2016